

=> fil reg; d ide

~~FILE 'REGISTRY'~~ ENTERED AT 15:06:34 ON 11 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 APR 2005 HIGHEST RN 848184-66-7
DICTIONARY FILE UPDATES: 10 APR 2005 HIGHEST RN 848184-66-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 648864-11-3 REGISTRY
ED Entered STN: 11 Feb 2004
CN 1H-Pyrazole-3-propanoic acid, α -(3-chlorophenyl)-1-(2,5-
dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-(3-Chlorophenyl)-3-[1-(2,5-dichlorophenyl)-5-(naphthalen-2-yl)-1H-
pyrazol-3-yl]propionic acid
FS 3D CONCORD
MF C28 H19 Cl3 N2 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

*species*

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil_capl uspatf toxcenter; s 15

FILE 'CAPLUS' ENTERED AT 15:06:46 ON 11 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:06:46 ON 11 APR 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 15:06:46 ON 11 APR 2005

COPYRIGHT (C) 2005 ACS

L6 6 L5

=> dup_rem_l6

PROCESSING COMPLETED FOR L6

L7 5 DUP REM L6 (1 DUPLICATE REMOVED)

ANSWERS '1-2' FROM FILE CAPLUS

ANSWERS '3-5' FROM FILE USPATFULL

=> d ibib ed abs hitstr 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:60479 CAPLUS

DOCUMENT NUMBER: 140:128414

TITLE: Preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators

INVENTOR(S): Barrett, Terrance D.; Breitenbucher, J. Guy; Gomez, Laurent; Hack, Michael D.; Huang, Liming; McClure, Kelly J.; Morton, Magda F.; Sehorn, Clark A.; Shankley, Nigel P.

agb


PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
 SOURCE: PCT Int. Appl., 326 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007463	A1	20040122	WO 2003-US20787	20030702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004067983	A1	20040408	US 2003-612150	20030702
PRIORITY APPLN. INFO.:			US 2002-393493P	P 20020703

OTHER SOURCE(S): MARPAT 140:128414

ED Entered STN: 26 Jan 2004

GI



AB The title compds. [I; R1 = 1- or 2-position substituent selected from H, (un)substituted Ph, naphthyl, etc.; R2 = (un)substituted Ph, naphthyl, Ph or pyridyl fused to 3-4 membered hydrocarbon moiety to form a fused 5-6 membered aromatic ring, etc.; R3 = H, halo, alkyl; n = 0-2; R4 = H, halo, alkyl, absent; Ar = (un)substituted Ph, naphthyl, Ph or pyridyl fused to 3-4 membered hydrocarbon moiety to form a fused 5-6 membered aromatic ring, etc.; R5 = CO2R6 (wherein R6 = H, alkyl), CONR7R8 (R7, R8 = H, alkyl, cycloalkyl; or NR7R8 = 5-7 membered ring), tetrazolyl, etc.], useful as CCK-1 receptor modulators, were prepared E.g., a multi-step synthesis of (S)-II which showed pKi of 8.0 against CCK-1 receptor binding, was given. Pharmaceutical composition comprising the title compound was claimed.


IT 648864-11-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators)

RN 648864-11-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:55208 CAPLUS

DOCUMENT NUMBER: 142:155944

TITLE: Preparation of pyrazole derivatives as CCK-1 receptor modulators for the treatment of gastrointestinal and CNS disorders

INVENTOR(S): Choudhury, Anusuya; Grimm, Jeffrey S.; Jones, Todd K.; Liang, Jimmy T.; Mani, Neelakandha; Sorgi, Kirk L.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 353 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005393	A2	20050120	WO 2004-US21020	20040630
WO 2005005393	A3	20050224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005020565	A1	20050127	US 2004-882077	20040630
US 2005026903	A1	20050203	US 2004-881628	20040630

PRIORITY APPLN. INFO.:

US 2003-484319P





P 20030702

US 2003-484370P

P 20030702

ED Entered STN: 20 Jan 2005

GI



AB The invention relates to certain pyrazole based CCK-1 receptor modulators I [wherein R1 (1- or 2-position) = (un)substituted Ph, naphthyl, cycloalkyl, heterocyclyl or alkyl; R2, Ar = (un)substituted Ph, naphthyl, cycloalkyl or heterocyclyl; R3 = H, halo or alkyl; n = 0-2; R4 = H, halo, alkyl or absent when the double bond is present; R5 = COOH, ester, amide or certain triazolylsulf(a/o/i)nyl; etc., or enantiomers, diastereomers and pharmaceutically acceptable salts and esters thereof] and methods for their preparation. For example, condensation of 3,4-dichloroacetophenone with di-Et oxalate in the presence of LiHMDS followed by regioselective cyclization with 4-methoxyphenylhydrazine hydrochloride gave pyrazole II (R = COOEt). This ester was then converted to iodide II (R = CH2I) via DIBAL reduction, mesylation with methanesulfonyl chloride and substitution with NaI. Enantioselective alkylation of chiral oxazolidinone III (preparation given) with II (R = CH2I) followed by hydrolysis mediated by H2O2-LiOH afforded IV. Sodium salt of IV showed affinity for CCK-1 receptor with pKi of 8.0. Therefore, I are useful in treating diseases mediated by CCK receptors, such as gastrointestinal and CNS disorders.


IT **648864-11-3P**, 2-(3-Chlorophenyl)-3-[1-(2,5-dichlorophenyl)-5-(naphthalen-2-yl)-1H-pyrazol-3-yl]propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazole propionates as CCK-1 receptor modulators)

RN **648864-11-3** CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:31466 USPATFULL

TITLE: CCK-1 receptor modulators

INVENTOR(S): Choudhury, Anusuya, Churchville, PA, UNITED STATES
 Grimm, Jeffrey S., Somerville, NJ, UNITED STATES
 Liang, Jimmy T., San Diego, CA, UNITED STATES
 Mani, Neelakandha, San Diego, CA, UNITED STATES
 Sorgi, Kirk L., Doylestown, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005026903	A1	20050203
APPLICATION INFO.:	US 2004-881628	A1	20040630 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-484370P	20030702 (60)
	US 2003-484319P	20030702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	172	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8446	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided by the present invention certain pyrazole based CCK-1 receptor modulators which have the general formula: ##STR1##

wherein Ar is an aromatic or heteroaromatic group, X is a hydrocarbon linker, Y is a bond or hydrocarbon linker and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are certain organic substituents, and methods of making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 648864-11-3P, 2-(3-Chlorophenyl)-3-[1-(2,5-dichlorophenyl)-5-(naphthalen-2-yl)-1H-pyrazol-3-yl]propionic acid
(drug candidate; preparation of pyrazole propionates as CCK-1 receptor modulators)
RN 648864-11-3 USPATFULL
CN 1H-Pyrazole-3-propanoic acid, α -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:24016 USPATFULL

TITLE: CCK-1 receptor modulators

INVENTOR(S): Jones, Todd K., Solana Beach, CA, UNITED STATES
Liang, Jimmy T., San Diego, CA, UNITED STATES
Mani, Neelakandha, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005020565	A1	20050127
APPLICATION INFO.:	US 2004-882077	A1	20040630 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-484319P	20030702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	289	
EXEMPLARY CLAIM:	1	
LINE COUNT:	9023	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided by the present invention certain pyrazole based CCK-1 receptor modulators which have the general formula: ##STR1##


wherein Ar is an aromatic or heteroaromatic group, X is a hydrocarbon linker, Y is a bond or hydrocarbon linker and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are certain organic substituents, and methods of making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 648864-11-3P, 2-(3-Chlorophenyl)-3-[1-(2,5-dichlorophenyl)-5-(naphthalen-2-yl)-1H-pyrazol-3-yl]propionic acid
(drug candidate; preparation of pyrazole propionates as CCK-1 receptor modulators)

RN 648864-11-3 USPATFULL

CN 1H-Pyrazole-3-propanoic acid, α -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2004:89006 USPATFULL

TITLE: CCK-1 receptor modulators

INVENTOR(S): Barrett, Terrance D., Encinitas, CA, UNITED STATES
Breitenbucher, J. Guy, Escondido, CA, UNITED STATES
Gomez, Laurent, San Diego, CA, UNITED STATES
Hack, Michael D., San Diego, CA, UNITED STATES
Huang, Liming, San Diego, CA, UNITED STATES
McClure, Kelly J., San Diego, CA, UNITED STATES
Morton, Magda F., San Diego, CA, UNITED STATES
Sehon, Clark A., West Chester, PA, UNITED STATES
Shankley, Nigel P., Solana Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004067983	A1	20040408
APPLICATION INFO.:	US 2003-612150	A1	20030702 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-393493P	20020703 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8963	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 648864-11-3P

(preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators)

RN 648864-11-3 USPATFULL

CN 1H-Pyrazole-3-propanoic acid, α -(3-chlorophenyl)-1-(2,5-dichlorophenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



=> □

=> fil reg; d stat que l4

FILE 'REGISTRY' ENTERED AT 15:08:23 ON 11 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 APR 2005 HIGHEST RN 848184-66-7

DICTIONARY FILE UPDATES: 10 APR 2005 HIGHEST RN 848184-66-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*





Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

L1

STR



Cy = any cyclic group
Hy = heterocycle

REP G1=(0-2) CH2

VAR G3=H/X/12

VAR G5=14/COOH/18/20/21/22/25

NODE ATTRIBUTES:

NSPEC IS RC AT 19

CONNECT IS E2 RC AT 8

CONNECT IS E1 RC AT 12

CONNECT IS E1 RC AT 16

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY AT 26

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E2 C E3 N AT 26

heterocycle at node 26 is monocyclic with 2 carbons & 3 nitrogens

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L4 450 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 54293 ITERATIONS

SEARCH TIME: 00.00.01

450 ANSWERS

=> fil capl uspatf toxcenter; s l4

FILE 'CAPLUS' ENTERED AT 15:08:32 ON 11 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:08:32 ON 11 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 15:08:32 ON 11 APR 2005
COPYRIGHT (C) 2005 ACS

L10 15 L4

=> dup rem l10

PROCESSING COMPLETED FOR L10

L11 12 DUP REM L10 (3 DUPLICATES REMOVED)

ANSWERS '1-7' FROM FILE CAPLUS

ANSWERS '8-12' FROM FILE USPATFULL

=> d ibib ed abs hitstr 1-12; fil cao; s .l4

L11 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:60479 CAPLUS

DOCUMENT NUMBER: 140:128414

TITLE: Preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1
receptor modulatorsINVENTOR(S): Barrett, Terrance D.; Breitenbucher, J. Guy; Gomez,
Laurent; Hack, Michael D.; Huang, Liming; McClure,
Kelly J.; Morton, Magda F.; Sehorn, Clark A.;
Shankley, Nigel P.

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.

SOURCE: PCT Int. Appl., 326 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007463	A1	20040122	WO 2003-US20787	20030702
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004067983	A1	20040408	US 2003-612150	20030702

PRIORITY APPLN. INFO.: US 2002-393493P P 20020703

OTHER SOURCE(S): MARPAT 140:128414

ED Entered STN: 26 Jan 2004

GI



AB The title compds. [I; R1 = 1- or 2-position substituent selected from H, (un)substituted Ph, naphthyl, etc.; R2 = (un)substituted Ph, naphthyl, Ph or pyridyl fused to 3-4 membered hydrocarbon moiety to form a fused 5-6 membered aromatic ring, etc.; R3 = H, halo, alkyl; n = 0-2; R4 = H, halo, alkyl, absent; Ar = (un)substituted Ph, naphthyl, Ph or pyridyl fused to 3-4 membered hydrocarbon moiety to form a fused 5-6 membered aromatic ring, etc.; R5 = CO2R6 (wherein R6 = H, alkyl), CONR7R8 (R7, R8 = H, alkyl, cycloalkyl; or NR7R8 = 5-7 membered ring), tetrazolyl, etc.], useful as CCK-1 receptor modulators, were prepared E.g., a multi-step synthesis of (S)-II which showed pKi of 8.0 against CCK-1 receptor binding, was given. Pharmaceutical composition comprising the title compound was claimed.


IT 648862-87-7P 648862-96-8P 648862-98-0P
648863-12-1P 648863-73-4P 648864-29-3P
648864-52-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators)


RN 648862-87-7 CAPLUS

CN 1H-Pyrazole-3-propanamide, 1-(4-methoxyphenyl)- α -(3-methylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-96-8 CAPLUS

CN 1H-Indole-3-acetic acid, α -[[1-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl]methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 648862-98-0 CAPLUS

CN 1H-Indole-3-acetic acid, α-[[1-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl]methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 648863-12-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-bromophenyl)-α-(3-methylphenyl)-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648863-73-4 CAPLUS

CN Benzeneacetic acid, 3-chloro-α-[[5-(3,4-dichlorophenyl)-1-(4-ethoxyphenyl)-1H-pyrazol-3-yl]methylene]-, (αZ)- (9CI) (CA INDEX NAME)


NAME)

Double bond geometry as shown.




RN 648864-29-3 CAPLUS

CN 1H-1,2,4-Triazole, 3-[[3-[1,5-bis(4-methylphenyl)-1H-pyrazol-3-yl]-2-(3-methylphenyl)propyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 648864-52-2 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)-α-(3-methylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT 119540-46-4P 119540-49-7P 648861-58-9P
 648861-60-3P 648861-62-5P 648861-65-8P
 648861-67-0P 648861-70-5P 648861-72-7P
 648861-74-9P 648861-76-1P 648861-78-3P

648861-80-7P 648861-82-9P 648861-84-1P
648861-86-3P 648861-88-5P 648861-90-9P
648861-92-1P 648861-94-3P 648861-96-5P
648861-98-7P 648862-00-4P 648862-02-6P
648862-05-9P 648862-07-1P 648862-09-3P
648862-11-7P 648862-13-9P 648862-15-1P
648862-17-3P 648862-19-5P 648862-21-9P
648862-23-1P 648862-25-3P 648862-27-5P
648862-29-7P 648862-31-1P 648862-33-3P
648862-35-5P 648862-37-7P 648862-39-9P
648862-41-3P 648862-43-5P 648862-45-7P
648862-47-9P 648862-49-1P 648862-51-5P
648862-53-7P 648862-55-9P 648862-57-1P
648862-59-3P 648862-61-7P 648862-63-9P
648862-65-1P 648862-67-3P 648862-69-5P
648862-71-9P 648862-73-1P 648862-75-3P
648862-77-5P 648862-79-7P 648862-81-1P
648862-83-3P 648862-85-5P 648862-90-2P
648862-92-4P 648862-94-6P 648863-00-7P
648863-02-9P 648863-06-3P 648863-08-5P
648863-10-9P 648863-14-3P 648863-16-5P
648863-18-7P 648863-20-1P 648863-22-3P
648863-24-5P 648863-26-7P 648863-28-9P
648863-31-4P 648863-33-6P 648863-35-8P
648863-37-0P 648863-39-2P 648863-41-6P
648863-43-8P 648863-45-0P 648863-47-2P
648863-49-4P 648863-51-8P 648863-53-0P
648863-55-2P 648863-57-4P 648863-59-6P
648863-61-0P 648863-63-2P 648863-65-4P
648863-67-6P 648863-69-8P 648863-71-2P
648863-75-6P 648863-77-8P 648863-79-0P
648863-81-4P 648863-83-6P 648863-85-8P
648863-87-0P 648863-89-2P 648863-91-6P
648863-93-8P 648863-95-0P 648863-97-2P
648863-99-4P 648864-01-1P 648864-03-3P
648864-05-5P 648864-07-7P 648864-09-9P
648864-11-3P 648864-13-5P 648864-15-7P
648864-17-9P 648864-19-1P 648864-21-5P
648864-23-7P 648864-25-9P 648864-27-1P
648864-31-7P 648864-33-9P 648864-35-1P
648864-37-3P 648864-39-5P 648864-41-9P
648864-43-1P 648864-45-3P 648864-48-6P
648864-50-0P 648864-54-4P 648864-56-6P
648864-58-8P 648864-60-2P 648864-62-4P
648864-64-6P 648864-66-8P 648864-68-0P
648864-70-4P 648864-72-6P 648864-74-8P
648864-76-0P 648864-78-2P 648864-80-6P
648864-82-8P 648864-84-0P 648864-86-2P
648864-88-4P 648864-90-8P 648864-92-0P
648864-94-2P 648864-96-4P 648864-98-6P
648865-00-3P 648865-02-5P 648865-04-7P
648865-06-9P 648865-08-1P 648865-10-5P
648865-12-7P 648865-14-9P 648865-16-1P
648865-18-3P 648865-20-7P 648865-22-9P
648865-24-1P 648865-26-3P 648865-28-5P
648865-30-9P 648865-32-1P 648865-34-3P
648865-36-5P 648865-38-7P 648865-40-1P
648865-42-3P 648865-44-5P 648865-46-7P
648865-48-9P 648865-50-3P 648865-52-5P
648865-54-7P 648865-56-9P 648865-58-1P


648865-60-5P 648865-62-7P 648865-64-9P
 648865-66-1P 648865-68-3P 648865-70-7P
 648865-72-9P 648865-74-1P 648865-76-3P
 648865-78-5P 648865-80-9P 648865-82-1P
 648865-84-3P 648865-86-5P 648865-88-7P
 648865-90-1P 648865-92-3P 648865-94-5P
 648865-96-7P 648865-98-9P 648866-00-6P
 648866-02-8P 648866-04-0P 648866-06-2P
 648866-08-4P 648866-10-8P 648866-12-0P
 648866-14-2P 648866-16-4P 648866-18-6P
 648866-20-0P 648866-22-2P 648866-24-4P
 648866-26-6P 648866-28-8P 648866-30-2P
 648866-32-4P 648866-34-6P 648866-36-8P
 648866-38-0P 648866-40-4P 648866-42-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators)


RN 119540-46-4 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α ,5-bis(4-chlorophenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 119540-49-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)-5-(4-methylphenyl)- α -2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 648861-58-9 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)- α -(3-methylphenyl)-, sodium salt, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● Na


RN 648861-60-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)-
α-(3-methylphenyl)- (9CI) (CA INDEX NAME)

RN 648861-62-5 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)-
α-(3-methylphenyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 648861-65-8 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, α,1-bis(4-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648861-67-0 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, α -(3-methoxyphenyl)-1-(4-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

RN 648861-70-5 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, α -(3-chlorophenyl)-1-(4-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

RN 648861-72-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)- α ,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648861-74-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α -(4-chlorophenyl)-1-(4-methoxyphenyl)-
5-(4-methylphenyl)- (9CI) (CA INDEX NAME)


RN 648861-76-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(2-chlorophenyl)-1-(4-methoxyphenyl)-
 α -1-naphthalenyl- (9CI) (CA INDEX NAME)

RN 648861-78-3 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(2-chlorophenyl)- α -(3-chlorophenyl)-
1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

RN 648861-80-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)-
 α -phenyl- (9CI) (CA INDEX NAME)

RN 648861-82-9 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)- α -(3-methoxyphenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 648861-84-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, α -3-benzofuranyl-1,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

RN 648861-86-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)- α -2-naphthalenyl-5-phenyl- (9CI) (CA INDEX NAME)


RN 648861-88-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)- α -(3-nitrophenyl)-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648861-90-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α -1,3-benzodioxol-4-yl-5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648861-92-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)- α -(2,3-difluorophenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648861-94-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)- α -[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 648861-96-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-α-(3-ethoxyphenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648861-98-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)-α-[2-fluoro-3-(trifluoromethyl)phenyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-00-4 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(4-methoxyphenyl)-5-(4-phenoxyphenyl)-α-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-02-6 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)-
α-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)


RN 648862-05-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)-α-(3-
iodophenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

RN 648862-07-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)- α -(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)

RN 648862-09-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)-5-(4-methylphenyl)- α -[3-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)

RN 648862-11-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)- α -1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 648862-13-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)- α -1-naphthalenyl-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648862-15-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)- α -1-naphthalenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648862-17-3 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, α -(3-methoxyphenyl)-1,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 648862-19-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α -(3-methoxyphenyl)-1,5-bis(4-methoxyphenyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648862-21-9 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, α -(3-methoxyphenyl)-1,5-bis(4-methoxyphenyl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648862-23-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α -[1,1'-biphenyl]-4-yl-5-(4-chlorophenyl)-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648862-25-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)- α -(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-27-5 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)- α -(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648862-29-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(4-chlorophenyl)-α-(3-methoxyphenyl)-
1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

RN 648862-31-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α-(3-chlorophenyl)-5-(4-chlorophenyl)-
1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


RN 648862-33-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(4-chlorophenyl)-5-(4-methylphenyl)-
α-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 648862-35-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α ,1-bis(3-chlorophenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648862-37-7 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, α -(3-methylphenyl)-1,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648862-39-9 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(4-methylphenyl)- α -phenyl-1-[4-

(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)




RN 648862-41-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-(3,4-dichlorophenyl)-α-(3-methoxyphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-43-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α-(2-chlorophenyl)-5-(4-methylphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 648862-45-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-methylphenyl)-1-(phenylmethyl)-α-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-47-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-methylphenyl)-α-2-naphthalenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 648862-49-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α-(2,3-dichlorophenyl)-1-(3,4-dichlorophenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-51-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α-(3-methylphenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 648862-53-7 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 3-(3,4-dichlorophenyl)-1-methyl-α-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-55-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-1-methyl-α-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-57-1 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 1-cyclohexyl-α-(3-methylphenyl)-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 648862-59-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-cyclohexyl- α -(3-methylphenyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


RN 648862-61-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α -(3-methylphenyl)-5-(2-naphthalenyl)-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 648862-63-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-[4-(1,1-dimethylethyl)phenyl]-α-(3-methylphenyl)-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 648862-65-1 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(3,4-dichlorophenyl)-α-(3-methylphenyl)-1-[4-(methanesulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-67-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(1,3-benzodioxol-5-yl)-1-(2-chlorophenyl)-
 α -(3-methylphenyl)- (9CI) (CA INDEX NAME)

RN 648862-69-5 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 1-(2,4-dichlorophenyl)- α -(3-methylphenyl)-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)

RN 648862-71-9 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3-chlorophenyl)-1-(2,4-dichlorophenyl)-
 α -(3-methylphenyl)- (9CI) (CA INDEX NAME)


RN 648862-73-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, α -(3-methylphenyl)-5-[4-(phenylmethoxy)phenyl]-1-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 648862-75-3 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-[4-(dimethylamino)phenyl]- α -(3-methylphenyl)-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-77-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(3-methoxy-4-methylphenyl)- α -(3-methylphenyl)-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-79-7 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-[3-(cyclopentyloxy)-4-methoxyphenyl]- α -(3-methylphenyl)-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-81-1 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 5-(4-bromo-3-methylphenyl)-α-(3-methylphenyl)-1-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 648862-83-3 CAPLUS


CN 1H-Pyrazole-3-propanoic acid, 5-(7-methoxy-2-benzofuranyl)-α-(3-methylphenyl)-1-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 648862-85-5 CAPLUS


CN 1H-Pyrazole-3-propanamide, N-[(1R,2R)-2-hydroxycyclohexyl]-1-(4-methoxyphenyl)- α -(3-methylphenyl)-5-(4-methylphenyl)-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 648862-90-2 CAPLUS

CN 1H-Pyrazole-3-propanamide, 1-(4-methoxyphenyl)-N,N-dimethyl- α -(3-methylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 648862-92-4 CAPLUS

CN 1H-Pyrazole-3-propanamide, 1-(4-methoxyphenyl)-N-methyl-α-(3-methylphenyl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 648862-94-6 CAPLUS

CN Piperazine, 1-[3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl]-2-(3-methylphenyl)-1-oxopropyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 648863-00-7 CAPLUS

CN 1H-Indole-3-acetic acid, α-[[1-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl]methyl]- (9CI) (CA INDEX NAME)